Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II infant study of M72/AS01E tuberculosis vaccine schedules
2012-004380-44Phase 2
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of M72 + AS01E in Tuberculosis (TB) (4 arms), sponsored by GSK. Primary endpoint: Grade 3 solicited adverse events.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2012-004380-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004380-44.